Abel Hall LLC’s Humacyte HUMA Stock Holding History

Abel Hall LLC’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,241	Closed	-$8.64K	–	1018
2026 Q1	$8.64K	Buy	+14,241	New	+$14.8K	﹤0.01%	805

Other funds holding HUMA

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Clarus Wealth Advisors Peoria, Arizona $260M AUM 27.97% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

V.M. Manning & Co Greenville, South Carolina $117M AUM

Abel Hall LLC's HUMA Position: Q2 2026 in Review

Abel Hall LLC sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 14,241 shares — an estimated $8.64K sold.

Abel Hall LLC first reported a position in HUMA in Q1 2026 and held it in 1 quarter. The position peaked at $8.64K in Q1 2026. 40 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Abel Hall LLC reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 14,241 Humacyte shares in Q2 2026, an estimated $8.64K.
Abel Hall LLC first reported a position in Humacyte in Q1 2026 and held it in 1 quarter.
Abel Hall LLC's Humacyte position peaked at $8.64K in Q1 2026.
40 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.